Windhover.com | Medtech Insight | The RPM Report | Inteleos | EBI
Subscriber Username:   Password: Forgot Password?
Health Care Business Intelligence, Analysis, Insight - Windhover
Search


Receive Windhover's unique market insight fast with our free alert service 'Windhover's Update', including the latest abstracts and summaries from:

• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight


Sign up now

FDA/CMS Summit 2010
REGISTER TODAY AND SAVE $500!
 Early Bird Registration Ends September 30th!
Interested in presenting at a Windhover conference?
Submit your idea here

Cancellation Policy:
The last day to cancel your registration for a refund, minus a $300 processing fee, is November 1, 2010. After that, you may send another delegate from your company.


Featuring the Special Keynote Addresses: FDA’s Public Health Priorities with

Margaret Hamburg
Commissioner
Food & Drug Administration (FDA)

and Update from CDER with
Janet Woodcock
Janet Woodcock, MD
Director, Center for Drug Evaluation & Research
Food & Drug Administration (FDA)

2010 Speakers Include:
Andy Wyss
Head Pharma North America President
Novartis Pharmaceuticals
Keynote
Robert Temple, MD
Deputy Director, Clinical Science
Center for Drug Evaluation & Research, FDA
Steven E. Nissen, MD, MACC
Chairman of the Department of Cardiovascular Medicine
The Cleveland Clinic
Robert Clark
Vice President, Worldwide Regulatory Strategy
Pfizer Inc.
Peter Honig
Head, Global Regulatory Affairs AstraZeneca
Roger M. Perlmutter, MD, PhD
Executive Vice President of Research & Development,
Amgen Inc.
Gerald Dal Pan, MD Director, Office of Surveillance & Epidemiology Center for Drug Evaluation & Research
FDA
Jonca Bull
Vice President,US Drug Regulatory Affairs Novartis
Head, FDA Liaison and Regulatory Policy Office

Landmark legislation will reshape the climate for biopharmaceutical companies.

What, again?

First the Medicare Modernization Act (2003) makes the federal government the dominant payor for pharmaceuticals, then the FDA Amendments Act (2007) redefines the regulatory model. Now, comes the Affordable Care Act (2010)—the most dramatic, system-wide change in the US health care sector ever. What will these changes mean for biopharmaceutical companies? Come to the FDA/CMS Summit to find out.

Health Care Reform: What’s Next?

Hear directly from leaders in government and industry about how health care reform will affect your business, How will development programs have to change to satisfy demands for comparative research? What pricing and reimbursement models will best position you for success? And where are the real opportunities for growth as the US healthcare market continues to evolve?

Last year’s conference was standing room only! Register now to reserve your seat.

If you make FDA/CMS Summit an annual must-attend like hundreds of other pharmaceutical and biotech leaders, keep ahead of the curve and mark your calendars NOW.

NEW for 2010! Hear the Regulators’ First-Hand Perspectives on:

  • Health Care Reform
  • New Drug Reviews
  • PDUFA V
  • Personalized Medicine
  • Comparative Effectiveness Research
  • Biosimilars/follow-on biologics
  • HCR Implementation
  • Payor Issues
  • Drug safety, risk management and post-market surveillance
  • Pharma marketing and promotions regulation and enforcement
  • Medicaid and Medicare reimbursement
  •  Medicare Part D
  • Critical Path Initiative
  • Pricing Strategies

Key Benefits for Attending FDA/CMS Summit:

  • Hear about critical trends and changes so you can create successful strategies for dealing with FDA and CMS
  • Walk away with practical, real life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles
  • Get face-to-face access to the top regulatory thought leaders and policy makers
  • Benchmark your regulatory strategy against all the major pharmaceutical and biotech companies

Here is what your peers have to say about FDA/CMS Summit:

"I would like to thank the whole Windhover/RPM team for putting together this conference. Conferences are made by its participants and the group assembled here today is so diverse and truly experienced."
- Mark McClellan, MD/PhD, Former FDA Commissioner and CMS Administrator

"Summit provided a rare opportunity for a broad group of life science companies and regulators to interact in a frank, yet cooperative manner. Great opportunity to learn from peers and our FDA / CMS customer."
- David McNinch, Affymax, Sr. Director of Marketing

"Nobody does it better!!! Best healthcare business policy conference of the year."
- John Kamp, Executive Director, Coalition for Healthcare Communication

"Great speakers. Slides were well done - informative, not just fluff."

"Fostered networking times very useful."

"Excellent information from the best sources with regard to what to expect in Washington under the new Obama Administration."

"When the right people are invited as speakers, it makes for an exceptional conference."

"Excellent speakers, well-organized event and widely-attended."

"A very valuable conference, showcasing great insights into the framework of US regulatory bodies."

"All the up to date information on emerging trends in FDA and CMS policy presented in one place at one time by the people that make the policy."

"An important opportunity to step back and take an integrated look at the macro trends that will affect industry activity next year and beyond."

"From a European perspective and without being a regulatory expert, the summit certainly provided great insights into the current and future challenges related to FDA and CMS."

"I found the agenda to be comprehensive and balanced and was happy with the high caliber list of speakers."

"The agenda covered all the important background as well as "breaking news" in the key regulatory areas affecting our industry."

"The conference really showed that these two organizations have more in common than differences."

"The Summit was an impressive gathering of current and former FDA and CMS officials who provided valuable perspectives on policy slated for debate in 2006."

"Topics were of high relevance and speakers very impactful. A timely and informative conference."

"Valuable curriculum and great line-up of speakers. A great program for regulatory, government and marketing personnel."

A small sample of companies who send their teams to FDA/CMS Summit include:

Affymax, Inc.

Allergan, Inc.

Amgen Inc.

Amylin Pharmaceuticals, Inc.

AstraZeneca

Bayer Schering Pharma AG

Boehringer Ingelheim Corp.

Bristol-Myers Squibb Company

Cell Therapeutics Inc. (CTI)

Cephalon

CGI Pharmaceuticals Inc.

Dendreon

Eli Lilly and Company

EMD Serono, Inc.

Endo Pharmaceuticals, Inc

F. Hoffmann La Roche

FDA - CDER

Genentech Inc.

Johnson & Johnson

McKesson Corp.

Merck & Co Inc.

Neurocrine Biosciences Inc.

Novartis Pharmaceuticals

Novexel Inc

Ovation Pharmaceuticals Inc.

Pfizer, Inc.

PTC Therapeutics

Purdue Pharma LP

Sanofi Aventis

Schering-Plough Corp.

Sepracor Inc.

Takeda Pharmaceuticals North American LTD.

Teva Neuroscience

UCB Pharma

Vertex Pharmaceuticals Inc.

Wyeth

XenoPort Inc


Global Sponsor:



Silver Sponsor:

Gerson Lehman Group

Association Sponsor:

 BIOTECanada


Media Partners:













Don’t fall behind the curve. Seating is limited. Register online today and save.

For more information contact Pat Cardone at (203) 838-4401 x124, or p.cardone@elsevier.com.

We look forward to greeting you in Washington DC!


The IN VIVO Blog

Pharmaceutical Strategic Alliances
September 21-23, 2010 · New York, NY

PharmAsia Summit
October 25-26, 2010 · San Francisco, CA

IN3 Summit
October 27-29, 2010 · San Francisco, CA

Interested in presenting at a Windhover conference?
Submit your idea here


Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs. . . [MORE] (IN VIVO)

Bioactive Technologies For Bone Replacement
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. . . [MORE] (Start-Up)

Laser Cataract Surgery Comes into Focus at ASCRS
The mood was primarily upbeat at April's annual meeting of the American Society of Cataract and Refractive Surgery. Most in attendance expected a modest rebound in procedure volumes for 2010. . . [MORE] (Medtech Insight)

FDA, Drug Development and Health Care Reform: A Panel Discussion
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development. . . [MORE] (The RPM Report)

Read more from the latest: IN VIVO, Start-Up, The RPM Report, Medtech Insight, "The Pink Sheet", "The Pink Sheet" DAILY, "The Rose Sheet", "The Tan Sheet", PharmAsia News, Pharmaceutical Approvals Monthly, and "The Gray Sheet".




Pharma Deals
  FDA Has Full Plate This Fall for Vaccines: More Than H1N1
  GSK Slides Away From Innovation
  The Billion Dollar REMS: Xenazine?
Device Deals
  Stroke Devices: Facing Challenges Head On
  Vascular Closure Devices at the Crossroads
  What New Her2 Tests Say about Personalized Medicine

Interested in subscribing? Click here.
Publications - Databases - Conferences - Webinars - About Us - Contact Us - Help - The IN VIVO Blog - RSS Feeds - Company Profiles - Subscriber Login

Copyright © 2010, Windhover Information, Inc. An Elsevier company. All rights reserved.

Elsevier Business Intelligence